After disappointing phase 3 trial results in ALS, Amylyx will pull Relyvrio from the market but provide it free to patients who want to stay on the medication.
The preserved brains, found on every continent except Antarctica, are offering neuroscientists and archaeologists unprecedented insights into neurodegenerative conditions.